Assessing rare disease understanding: a novel disease readiness level framework.

Area of Science:

• Medical research
• Rare disease studies
• Drug development

Background:

• Drug development for rare diseases faces prioritization challenges due to small market sizes.
• Existing incentive policies for orphan drugs lack established evaluation methods for resource allocation.
• A need exists for methods to measure rare disease understanding and compare it with other diseases to promote R&D.

Purpose of the Study:

• To propose a grading system, the Disease Readiness Level (DRL), for simultaneously measuring rare disease understanding and product development progress.
• To establish a framework that aids in the evaluation of rare diseases warranting resource support.

Main Methods:

• Adapted the National Aeronautics and Space Administration's Technology Readiness Levels (TRL) framework to create the DRL.
• Incorporated clinical guidelines and extended assessment to earlier stages than traditional product development.
• Conducted case studies using the DRL framework on four rare diseases: muscular dystrophy, progressive fibrodysplasia ossificans, Tangier disease, and idiopathic peripheral pulmonary artery stenosis.

Main Results:

• The DRL framework comprehensively described the progression of the four selected rare diseases from origin to therapeutic strategies.
• The DRL covered a longer assessment period than existing TRL derivatives, from pre-product development to launch.
• Case studies demonstrated the DRL's ability to analyze disease understanding and R&D progress.

Conclusions:

• The developed DRL framework offers a comprehensive approach to assessing rare diseases, focusing on the disease itself from discovery to drug development.
• The DRL framework can analyze both the level of understanding of rare diseases and the progress of product R&D.
• The DRL serves as a potential indicator for allocating R&D resources effectively for rare diseases.